The United Kingdom and the United States have hammered out a key commercial pact that will guarantee zero tariffs on UK drug exports entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This pledge guarantees that tariffs on these key goods will be held at nothing for a duration of three years.
This agreement follows previous threats to dramatically increase tariffs on patented drug imports, with figures discussed up to one hundred percent.
"This agreement between the United Kingdom bolsters the worldwide climate for new treatments and establishes long-overdue fairness to American-British pharmaceutical trade," a release noted.
Trade Significance
Drugs constitute one of the the United Kingdom's most significant exports to the US, which is clearly the primary market for leading companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to last September, the UK exported drugs valued at over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This deal safeguards jobs, increases investment and paves the way for the UK to become a global hub for biotech and pharma," a minister commented.
Detailed UK Commitments
The agreement includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped 20%.
Recent Tensions
The pact comes amid a ongoing tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were intensified by arguments that American consumers were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had declined as a percentage of its overall budget over the past decade.
